<?xml version="1.0" encoding="UTF-8"?>
<p id="para0080">Dexamethasone could have an immediate impact on most severe cases of COVID-19. Recent results revealed that this drug could reduce the mortality rate to one-third and one-fifth in COVID-19 patients who are on ventilators and supplemental oxygen respectively. Dexamethasone didn't show any significant beneficial effect in patients who did not require respiratory support.
 <xref rid="bib0075" ref-type="bibr">
  <sup>75</sup>
 </xref> There are controversial comments on the usage of NSAIDs in the treatment of COVID-19. A possible disadvantage of NSAIDs such as Ibuprofen in COVID-19 infection is their potential effects in over-expression of ACE2 and enhancement of angiotensin II, which could worsen the clinical course of COVID-19 pneumonia. Another possible disadvantage of NSAIDs is their masking effect which can delay the diagnosis of COVID-19 infection.
 <xref rid="bib0068" ref-type="bibr">
  <sup>68</sup>
 </xref>
</p>
